Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.
On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Smoking Cessation Program in the Preadmission Clinic
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2010-04-08
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 290
- Registration Number
- NCT00937508
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
Treatment of Smoking Among Individuals With PTSD
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 142
- Registration Number
- NCT00937235
- Locations
- 🇺🇸
University of Pennsylvania School of Medicine, Dept of Psychiatry, Center for Treatment and Study of Anxiety, Philadelphia, Pennsylvania, United States
Varenicline and Bupropion for Smoking Cessation
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 506
- Registration Number
- NCT00935818
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University Of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Franciscan Skemp Hospital, LaCrosse, Wisconsin, United States
Impact of Varenicline on Blood-Oxygen-Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation on Smokers
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 21
- Registration Number
- NCT00934024
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Efficacy and Safety of Varenicline Among HIV-infected Patients
- Conditions
- Interventions
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 248
- Registration Number
- NCT00918307
- Locations
- 🇫🇷
CHU de Bordeaux, Bordeaux, France
Methadone Maintenance Treatment and Smoking Cessation
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Vancouver Coastal Health
- Target Recruit Count
- 112
- Registration Number
- NCT00906386
- Locations
- 🇨🇦
Three Bridges Community Health Centre, Vancouver, British Columbia, Canada
Assessing the Impact of Varenicline on Brain-Behavior Vulnerability
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2016-09-08
- Lead Sponsor
- University of Pennsylvania
- Registration Number
- NCT00895557
- Locations
- 🇺🇸
University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States
A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00889720
- Locations
- 🇮🇹
Pfizer Investigational Site, Pisa, Italy
Smoking Study With Behavioral Therapy for Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- UConn Health
- Target Recruit Count
- 203
- Registration Number
- NCT00879177
- Locations
- 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
Effect of Varenicline on Reactivity to Smoking and Drinking Cues
- Conditions
- Interventions
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 48
- Registration Number
- NCT00873535
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.